Clinical trials: HIV Lipodystrophy Syndrome
Lipodystrophy
Egrifta Replacement and Sleep Disordered Breathing
Sleep-disordered breathing is characterized primarily by partial or total upper airway obstruction during sleep. The most common form of sleep-disordered breathing is obstructive sleep apnea (OSA) due to recurrent collapse of the…
- Trial name
- NCT01788462
- Testing
- Tesamorelin (Egrifta)
- Where
- United States
- Sponsor
- Johns Hopkins University
HIV Infection
SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function
HIV infected subjects receiving antiretroviral treatment for greater than 6 years with be evaluated for clinical lipoatrophy and mitochondrial function after switching nucleoside analogues from stavudine (d4T) to tenofovir…
- Trial name
- NCT00225082
- Testing
- Nucleoside analogue switch
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
HIV-associated Lipodystrophy Syndrome
An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects
This will be a two-part study in healthy adults. Part A is a phase 1, non-randomized, open label, single-dose, single-centre mass balance study utilizing a radiolabeled dose to investigate the recovery, excretion, and…
- Trial name
- NCT01848340
- Testing
- GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV-Associated Lipodystrophy Syndrome
Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome
The purpose of this clinical research study is to learn if human immunodeficiency virus (HIV)-infected subjects with abdominal fat accumulation on their highly active antiretroviral treatment (HAART) regimen have better changes…
- Trial name
- NCT00135356
- Testing
- Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs), continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
- Where
- 30 sites in United States, Canada and 7 more
- Volunteers
- 219 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections, Lipodystrophy
Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids
The purpose of this study is to compare the safety and effectiveness of fenofibrate and pravastatin in treating HIV-positive patients who have abnormal levels of fat (lipids) in the blood.
- Trial name
- NCT00006412
- Testing
- Pravastatin sodium, Fenofibrate
- Where
- 58 sites in United States, Puerto Rico
- Volunteers
- 630 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV Wasting Syndrome
The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children
The purpose of this study is to see how beginning or changing anti-HIV medications affects the body composition (weight, height, growth, body fat, and muscle mass, or fat and muscle distribution) of HIV-infected children.
- Conditions
- HIV Infections, HIV Wasting Syndrome, Lipodystrophy
- Trial name
- NCT00006064
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Lipodystrophy
TH9507 in Patients With HIV-Associated Lipodystrophy
HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation and loss of extremity and subcutaneous fat, in…
- Trial name
- NCT00123253
- Testing
- TH9507
- Where
- 42 sites in United States, Canada
- Volunteers
- 412 people
- Sponsor
- Theratechnologies
Metabolic Syndrome, HIV-1-infection
Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH.
With current antiretroviral therapy, people living with HIV reach virological suppression faster, which in turn leads to a higher life expectancy.
- Conditions
- Metabolic Syndrome, HIV-1-infection, Glucose Intolerance, Dyslipidemias
- Trial name
- BERMESyH (NCT04860063)
- Testing
- Berberine
- Volunteers
- 40 people
- Sponsor
- Hospital Civil de Guadalajara
HIV Infections
Long-Term Data Collection From Participants in Adult AIDS Clinical Trials
The purpose of this study is to determine what combinations of anti-HIV drugs work best in patients treated over several years. The study will also assess the occurrence of side effects and opportunistic infections in patients…
- Trial name
- NCT00001137
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 5,982 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency
Body Composition and Adipose Tissue in HIV
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity.
- Conditions
- HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
- Trial name
- NCT03226821
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
HIV Infections, Lipodystrophy
The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients
The purpose of this study is to investigate the effect of low-dose human growth hormone therapy on immune status and fat morphology.
- Trial name
- NCT00119769
- Testing
- Genotropin (human recombinant Growth hormone)
- Where
- Denmark
- Volunteers
- 46 people
- Sponsor
- Hvidovre University Hospital
HIV Infections
A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications
The purpose of this study is to see if it is safe and effective to give the protease inhibitor (PI) amprenavir (APV) to patients with fat production and distribution problems associated with other PIs.
- Trial name
- NCT00002417
- Testing
- Amprenavir
- Where
- United States
- Sponsor
- Glaxo Wellcome
Cardiovascular Diseases, Heart Diseases
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
This study will evaluate the efficacy of diet and exercise (DE), with and without niacin and fenofibrate, in reducing the cardiovascular risk of patients with HIV lipodystrophy or dyslipidemia.
- Conditions
- Cardiovascular Diseases, Heart Diseases, HIV Infections, Hyperlipidemia
- Trial name
- HeartPositive (NCT00246376)
- Testing
- Diet, Exercise, Niacin
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- Baylor College of Medicine
HIV-Associated Lipodystrophy Syndrome
Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome
The hypotheses of this study were that: 1. HIV lipodystrophy is associated with psychological morbidity relating to body image, anxiety and depression. 2.
- Trial name
- NCT01359917
- Volunteers
- 50 people
- Sponsor
- NHS Lothian
HIV Infection, Antiretroviral Side Effects
Polyacrylamide Hydrogel Injection in HIV-related Lipoatrophy
Combined antiretroviral therapy (cART) is associated with facial lipoatrophy, which is potentially stigmatizing for HIV-positive patients.
- Conditions
- HIV Infection, Antiretroviral Side Effects, Lipodystrophy Syndrome Related to HIV Infection
- Trial name
- LIPOPHILL (NCT01077765)
- Testing
- Eutrophill
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Infections, Lipodystrophy
Changing to Nonprotease Inhibitor Treatment to Improve Side Effects
The purpose of this study is to learn whether changing from a type of anti-HIV drug called a protease inhibitor (PI) to another type of anti-HIV drug will help to lower the amount of fats or sugars in the blood.
- Trial name
- NCT00021463
- Testing
- Abacavir sulfate, Lamivudine and Zidovudine, Abacavir sulfate, Efavirenz
- Where
- 11 sites in United States
- Volunteers
- 342 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, HIV-Infections
The Visceral Adiposity Measurement and Observation Study
The Visceral Adiposity Measurement and Observation Study
- Conditions
- HIV, HIV-Infections, HIV-1-infection, HIV I Infection
- Trial name
- VAMOS (NCT05383456)
- Testing
- Diagnostic Test, HIV Anti-retroviral Background Therapy
- Where
- 8 sites in United States
- Volunteers
- 196 people
- Sponsor
- Theratechnologies
HIV Infections, Healthy
Metabolism and Body Shape of Healthy Children and Children With Chronic Infections
Some HIV-infected adults develop lipodystrophy that includes significant changes in body shape, with fat losses in the face, arms and legs, and fat gain in the trunk.
- Conditions
- HIV Infections, Healthy, Hyperlipidemia, Lipodystrophy
- Trial name
- NCT00001142
- Where
- United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
HIV Infections
PREventing Progression of Adipose Tissue Redistribution
The main objective of the study is to assess changes in fat distribution over 48 weeks of treatment in patients who currently successfully use zidovudine (AZT) and lamivudine (3TC) as part of their regimen and who will either…
- Trial name
- NCT00389194
- Testing
- continuing AZT+3TC or switching AZT+3TC to TDF+ FTC
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- International Antiviral Therapy Evaluation Center
AIDS, HIV Infections
Physiologic Growth Hormone Effects in HIV Lipodystrophy
This study will investigate long-term, low-dose growth hormone administration in HIV-infected patients with reduced growth hormone (GH) secretion and increased visceral adiposity.
- Trial name
- NCT00100698
- Testing
- recombinant human growth hormone
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Massachusetts General Hospital